sim0718
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jul 10, 2024 (NCT06488755)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-4 receptor subunit alphaANTAGONIST
IL4R antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06477835 | Phase 3 | Oct 15, 2024 | Peking University, Simcere Pharmaceutical Co., Ltd |
| NCT06488755 | Phase 3 | Jul 10, 2024 | Simcere Pharmaceutical Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Simcere Pharmaceutical Co., Ltd | For profit | 2 | 2 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1